Dream Incubator leads health-tech firm NIRAMAI’s Series A funding
Category: #health  By Shikha Sinha  Date: 2019-02-26
  • share
  • Twitter
  • Facebook
  • LinkedIn

Dream Incubator leads health-tech firm NIRAMAI’s Series A funding

NIRAMAI Health Analytix Pvt. Ltd., the Bengaluru-based breast cancer screening start-up, has reportedly raised around $6 million in Series A investment round that was led by Dream Incubator, a management consulting firm headquartered in Tokyo. Reportedly, Eto Munehiko, the Managing Director at Dream Incubator Advisory & Investment, India, will join NIRAMAI on board.

As per trusted sources, existing investors including Ankur Capital, Binny Bansal, pi Ventures and Axilor Ventures, along with Singapore-based venture fund Beenext, also participated in the funding round. Sources further cite that the start-up is anticipated to utilize the funds for scaling its Indian operations, hiring leading talent and seeking additional regulatory approvals for overseas expansion.

It has been reported that NIRAMAI has developed a non-contact, radiation-free device called Thermalytix, for early-stage breast cancer detection. A report by The Economic Times claims Dr. Geetha Manjunath, CEO, NIRAMAI, to have stated that if the NIRAMAI Thermalytix is institutionalised as a regular screening method, it endorses the potential to save numerous lives from breast cancer and other diseases as well.

Eto Munehiko was recently reported saying that the Tokyo-based company is excited to partner with NIRAMAI and believes firmly in the potential of its technology to deal better with global health issues at large. Eto further commented that Dream Incubator, having invested in over 160 companies, aims to support the international growth of NIRAMAI.

NIRAMAI, for those uninitiated, stands for non-invasive risk assessment with machine intelligence. The company uses artificial intelligence, together with big data analytics, to diagnose breast cancer at a prior stage. Its screening method, which is based on thermography principles, can detect tumours immensely earlier (about 5 years before) than a mammography or clinical examination usually takes. The start-up’s non-invasive, radiation-free device adds to its USP and further provides over 20 hospitals and diagnostic centres with training, installation and services, across Mysore, Bangalore, Dehradun, Pune, Mumbai and Hyderabad.



About Author

Shikha Sinha

Email: [email protected]   

Shikha Sinha

Shikha currently manages content operations for a series of news and business portals including MSF, Algosonline, and the like. An electrical & electronics engineer by education, she has prior experience in content & technology writing, content marketing, market resea...

Read More

More News By Shikha Sinha

Altimmune inks deal to acquire Spitfire Pharma and its NASH candidate
Altimmune inks deal to acquire Spitfire Pharma and its NASH candidate
By Shikha Sinha

Altimmune, Inc., a clinical stage biopharma company, has recently confirmed the closing of a formerly announced acquisition of Spitfire Pharma, Inc., including the strong GLP-1/Glucagon receptor co-agonist product cand...

NeurologyLive expands SAP program by partnering with Cleveland Clinic
NeurologyLive expands SAP program by partnering with Cleveland Clinic
By Shikha Sinha

NeurologyLive has reportedly added the Cleveland Clinic to its Strategic Alliance Partnership (SAP) program. Michael J. Hennessy Jr., President of NeurologyLive’s parent company MJH Associates Inc., said in a sta...

Neurocrine, Voyager reveal VY-AADC’s Phase I results at AAN 2019
Neurocrine, Voyager reveal VY-AADC’s Phase I results at AAN 2019
By Shikha Sinha

Neurocrine Biosciences Inc., along with Voyager Therapeutics Inc., has reportedly announced the Phase 1 results from the VY-AADC trial in eight patients suffering from Parkinson’s disease. Apparently, the patient...